Financing the frontier of healthcare.
Enabling groundbreaking discoveries.
We focus on innovative healthcare companies that deliver remarkable investment returns because of the tremendous value they generate for society.
Our independent, actionable insights power the hundreds of company and industry reports we publish each year.
We’ve successfully raised billions of dollars for healthcare innovators worldwide since 2015.
Our robust relationships can be leveraged through hundreds of hosted and sponsored events.
Our institutional equities team is made up of professionals averaging decades of focused experience.
At Chardan, we identified genetic medicines as an exemplar of disruptive innovation about 5 years ago. Since that time, we have built the leading global coverage in the space, with 28 names under coverage.
We are able to uncover the next big thing ahead of the rest of Wall Street because of our strong scientific foundation—evident in our industry-leading frameworks and weekly pieces—and our independent voice. Our influence extends beyond printed research to our hosted conferences, where we bring together the best companies, investors, and other industry innovators around the world.
Chardan’s genetic medicines practice is led by preeminent analyst Dr. Gbola Amusa, who has advised governments, NGOs, and other industry stakeholders on various healthcare policies and financial issues.
The microbiome medicines space appears to be on the verge of broad emergence after years of unfulfilled promise. 2019 has the potential to be significant with numerous trial initiations and multiple important data readouts throughout the year.
Chardan is a leading investment bank in the sector, covering more microbiome medicine names (7) than any other bank globally and producingThe Chardan Microbiome Medicines Landscape, a tool to segment the space and optimize investment returns.
Chardan’s Microbiome Medicines research effort is led by analyst Taylor Feehley, PhD. Dr. Feehley studied the microbiome and food allergies for her doctoral thesis; her work has been published in top-tier journals including Nature Medicine and PNAS, and was featured widely in the scientific and popular press in Science, Nature Microbiology, STAT, TIME, CBS News, and the BBC, among others. She was also named to the Forbes “30 Under 30” list for Science in 2016 for her work on the intestinal microbiome.
We identify and enable disruption within various segments in the biotech space. In addition to genetic medicines, our expertise spans areas such as cell therapy and regenerative medicine, immuno-oncology, vaccines, infectious diseases, hematology, lipids, ophthalmology, neurodegenerative disorders, rare diseases, and more.
Medicine and technology have historically been two separate endeavors, but we are now at a point where the two have meaningfully converged. Chardan is focused on being early to identify the winners and losers, and on bridging the gap between healthcare and technology.
Chardan considers digital therapeutics an emerging and transformative sub-segment of the prescription therapeutics space.
It is a space we view will generate a considerable number of winners in the coming years, as we have seen in a number of our existing areas of focus: e.g. gene therapy, RNA therapy, and cell therapy.
Therapeutics, Devices, and Diagnostics
At Chardan, we’re focused on new therapies and technologies that have the potential to transform clinical practice. This includes identifying the technologies that are enabling and supporting the development of new, patient-specific therapies that are targeted and customized.
Led by analyst Keay Nakae, a former electronic engineer who earlier in his career designed cardiac pacemakers. Over his 18-year career as an analyst, Keay has covered companies involved in cardiovascular, autoimmune, and infectious diseases, as well as oncology, ophthalmology, diabetes, cardiac and spine surgery, and aesthetics.
Amplify your success with Chardan.
Take your investment or venture to the next level. We’ll help you with mergers and acquisitions, equity financings, and everything in between.
Identify unique opportunities in cutting-edge verticals with access to our world-class research.
Attain financing on your private or public venture—from equity, debt, or convertible funding to IPO.
Tap into our exclusive global network through corporate access meetings, conferences, and events.
Meet our healthcare research team.
Gbola Amusa, MD, CFA
Partner, Director of Research, and Head of Healthcare Research
Geulah Livshits, PhD
Senior Research Analyst, Biotechnology and Pharmaceuticals
Keay Nakae, CFA
Senior Research Analyst, Device, Diagnostics, and Therapeutics
Senior Research Associate, Biotechnology and Pharmaceuticals
Meet our healthcare banking leadership.
We've received your information, and we're processing your request.